NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Key Information
Due Date: March 16, 2025
Agency: Not Specified
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: Not Specified
Funding Type: Grant, Government
Match Required: No
Contact Info:
grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
The ultimate objective of the program is to broaden the resource pool available to clinicians and patients with new technology, biological, and pharmaceutical offerings. A set of outlined steps or milestones should support the development of these therapeutics or devices. This will subsequently pave the way for applications to the U.S. Food and Drug Administration for Investigational New Drug (IND) or Investigational Device Exception (IDE) approvals or even for clinical trial testing.
The grant operates on a two-step, milestone-centric award system. The initial phase (R61) backs research projects that show crucial preliminary data but haven’t yet reached the clinical translation stage. The latter phase (R33) aids research that is on the brink of finishing preclinical development and possesses potential for quick clinical advancement. However, if a single phased award that doesn’t require the R61 exploratory stage is needed, support is available through the accompanying R33, PAR-23-205.
Key Dates
Open Date: June 27, 2023
Application Due Date: March 16, 2025
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses